Cytosorbents Corp

This proposal asks shareholders to approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the Proxy Statement (a standard “Say-on-Pay” request required by Section 14A of the Exchange Act). Management is seeking shareholder approval to confirm that its pay practices—base salaries, discretionary cash bonuses, and equity incentives—are aligned with long-term stockholder interests and competitive market practice to attract and retain key executives. The company emphasizes use of equity awards (restricted stock units and options) to align executives’ incentives with long‑term enterprise value and discloses adjustments made during 2024–2025 including voluntary salary reductions, deferred bonuses, and subsequent awards tied to performance and retention. Although the vote is advisory and non-binding, the Board and Compensation Committee state they will review and consider the outcome and may adjust programs if there is significant opposition. The key governance context includes the company’s status as a small-cap life sciences firm, capital‑raising needs, and ongoing regulatory and clinical development work (notably DrugSorb‑ATR development), which shape compensation decisions and retention risk. Potential investor objections could focus on deferred bonus payments, restoration of base salaries, timing and size of equity grants, or perceived pay-for-performance alignment given recent net losses; conversely, supporters will cite the use of long‑term equity and retention-focused structures. The Board’s recommendation frames the proposal as consistent with stockholder interests, while the advisory nature limits immediate legal effect—nonetheless, a strong negative vote would likely trigger substantive engagement and potential compensation program revisions. For an analyst, the critical evaluation should weigh whether disclosed metrics and vesting schedules effectively link pay to the company’s milestone-driven value creation and whether governance processes (Compensation Committee oversight, independent members) are sufficient to mitigate misalignment risks.

This management proposal would authorize an amendment to the Company’s Certificate of Incorporation empowering the Board to effect, at its discretion within one year, a reverse stock split of common shares at a ratio between 1‑for‑5 and 1‑for‑20. The Board’s stated motivation is principally to increase the per‑share market price to meet Nasdaq’s $1.00 minimum bid price requirement (the company received notice of noncompliance and has an extension to September 28, 2026), and to improve perceived marketability and institutional eligibility for the stock. The proposal grants the Board unilateral authority to choose the specific ratio and timing, conditioned on the Board’s determination that effecting the split is in the best interests of the Company and stockholders. Management argues the split would not change aggregate market capitalization or relative ownership percentages (except for rounding of fractional shares, which the company will round up to whole shares), and that equity awards and warrants would be proportionately adjusted. Risks highlighted include the possibility that the split may not produce a sustained price increase, could reduce liquidity and create more odd‑lot holders, and could effectively increase authorized-but-unissued shares — which the Board could later use (without additional shareholder approval) potentially affecting takeover dynamics. From a governance and investor perspective, the broad discretionary authority and range (1:5 to 1:20) give the Board flexibility but may raise concerns about dilution and post‑split market behavior; analysts should consider the split alongside the company’s capital needs, Nasdaq compliance timeline, and alternative strategies to restore the share price. If approved, the Board still may choose not to implement the split if market conditions improve, and failure to approve could increase the risk of Nasdaq delisting if the company cannot otherwise regain compliance.

This proposal seeks a contingent authorization to adjourn the Annual Meeting to a later date and time if, at the time of the meeting, there are not sufficient votes to approve one or more of the other proposals, thereby allowing additional solicitation of proxies. Management frames this as a routine procedural mechanism to avoid exercising an adverse outcome due solely to timing or incomplete proxy returns and to permit the Board to seek additional shareholder support. The measure is narrowly scoped—its only effect is procedural—and requires a majority of shares present and entitled to vote at the meeting to pass; it does not change the substance of any substantive proposal. For investors, the primary concern is that adjournment could be used to continue solicitation until desired outcomes are achieved; however, the company notes that adjournment also preserves stockholder rights because previously submitted proxies may be revoked prior to the adjourned vote. In practice, approval mitigates logistical risk (e.g., broker non‑votes, insufficient participation) and is commonly approved to provide flexibility in close votes, particularly when time‑sensitive matters (like the Nasdaq compliance timeline tied to the reverse split) are at stake. Analysts should note that if adjunctive to the reverse stock split vote, adjournment could extend the window for shareholder consideration and proxy solicitation, which may affect timing of any Board decision to implement the reverse split within the one‑year window. Overall, the proposal presents limited governance risk but is operationally important to permit orderly completion of the meeting’s business.